Earendil Labs, founded in 2021, is making waves in the Biotechnology sector with its innovative AI-driven approach to drug discovery. Under the compelling slogan "Transforming Drug Discovery: Next-Generation Protein Therapeutics Powered by AI," the company focuses on developing AI platforms that revolutionize protein therapeutics R&D. This technology backbone not only streamlines the discovery process but also accelerates the development of novel drugs, carving a niche in an increasingly competitive market.
In its latest financial milestone, the company secured a CNY5.42B investment during a Late VC round on 01 March 2026. This substantial funding round saw participation from notable investors such as DST Global, Luminous Ventures, INCE Capital, Sanofi, and Dimension Capital. These partnerships signal strong investor confidence in Earendil Labs' potential to significantly impact the biotechnology landscape with its cutting-edge AI solutions.
